{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:25:45Z","timestamp":1792218345281,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jbo.2025.100667","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T08:02:44Z","timestamp":1740729764000},"page":"100667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Zoledronic acid in metastatic castrate-sensitive prostate cancer: A state-of-the-art review"],"prefix":"10.1016","volume":"51","author":[{"given":"Nahed","family":"Damaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala","family":"Najdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah","family":"Seif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Nakouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jbo.2025.100667_b0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jbo.2025.100667_b0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/107327480601300302","article-title":"The role of prevalence in the diagnosis of prostate cancer","volume":"13","author":"Delongchamps","year":"2006","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.jbo.2025.100667_b0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.jbo.2025.100667_b0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.jbo.2025.100667_b0025","doi-asserted-by":"crossref","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. JCO. 2008;26(7):1148\u201359.","DOI":"10.1200\/JCO.2007.12.4487"},{"issue":"14","key":"10.1016\/j.jbo.2025.100667_b0030","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2017.76.4381","article-title":"Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer","volume":"36","author":"Szmulewitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2025.100667_b0035","unstructured":"A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). | Request PDF [Internet]. [cited 2025 Feb 15]. Available from: https:\/\/www.researchgate.net\/publication\/345634690_A_randomized_phase_II_cross-over_study_of_abiraterone_prednisone_ABI_vs_enzalutamide_ENZ_for_patients_pts_with_metastatic_castration-resistant_prostate_cancer_mCRPC."},{"issue":"13","key":"10.1016\/j.jbo.2025.100667_b0040","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.jbo.2025.100667_b0045","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2025.100667_b0050","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.jbo.2025.100667_b0055","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100667_b0060","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.34018","article-title":"Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)","volume":"151","author":"James","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.jbo.2025.100667_b0065","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2025.100667_b0070","unstructured":"ERLEADA\u00ae (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer [Internet]. [cited 2025 Feb 15]. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/erleada-apalutamide-demonstrates-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-compared-to-enzalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer."},{"key":"10.1016\/j.jbo.2025.100667_b0075","unstructured":"Clarke H. Apalutamide associated with improved 2-year survival vs enzalutamide in mCSPC. 2024 Oct 2 [cited 2025 Feb 15];53. Available from: https:\/\/www.urologytimes.com\/view\/apalutamide-associated-with-improved-survival-vs-enzalutamide-in-mcspc."},{"issue":"6","key":"10.1016\/j.jbo.2025.100667_b0080","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/1566524023362104","article-title":"Bisphosphonate mechanism of action","volume":"2","author":"Rodan","year":"2002","journal-title":"Curr. Mol. Med."},{"issue":"Suppl","key":"10.1016\/j.jbo.2025.100667_b0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF03026321","article-title":"The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib","volume":"23","author":"Mashiba","year":"2005","journal-title":"J. Bone Miner. Metab."},{"issue":"6","key":"10.1016\/j.jbo.2025.100667_b0090","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00520-013-1755-1","article-title":"Reducing the burden of bone metastases: current concepts and treatment options","volume":"21","author":"von Moos","year":"2013","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.jbo.2025.100667_b0095","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jbo.2025.100667_b0100","doi-asserted-by":"crossref","unstructured":"Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians, Barry MJ, et al. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017;166(11):818\u201339.","DOI":"10.7326\/M15-1361"},{"issue":"8","key":"10.1016\/j.jbo.2025.100667_b0105","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American society of clinical oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100667_b0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jbmr.3886","article-title":"Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates","volume":"35","author":"Pineda-Moncus\u00ed","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2025.100667_b0115","unstructured":"Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - PubMed [Internet]. [cited 2025 Feb 15]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34127184\/."},{"key":"10.1016\/j.jbo.2025.100667_b0120","unstructured":"Maximal androgen blockade therapy (MAB) for prostate cancer (PC) and risk of bone fractures: A systematic literature review and meta-analysis. | Request PDF [Internet]. [cited 2025 Feb 15]. Available from: https:\/\/www.researchgate.net\/publication\/381238043_Maximal_androgen_blockade_therapy_MAB_for_prostate_cancer_PC_and_risk_of_bone_fractures_A_systematic_literature_review_and_meta-analysis."},{"key":"10.1016\/j.jbo.2025.100667_b0125","first-page":"9","article-title":"How to improve the quality of life of patients with prostate cancer treated with hormone therapy?","volume":"15","author":"Turco","year":"2023","journal-title":"Res Rep Urol."},{"issue":"12","key":"10.1016\/j.jbo.2025.100667_b0130","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines\u2020","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100667_b0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41391-023-00775-y","article-title":"Safety profile of darolutamide versus placebo: a systematic review and meta-analysis","volume":"27","author":"Turco","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.jbo.2025.100667_b0140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100667_b0145","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/jbmr.1771","article-title":"Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy","volume":"28","author":"Greenspan","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.jbo.2025.100667_b0150","first-page":"870","article-title":"Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?","volume":"73","author":"Turco","year":"2021","journal-title":"Minerva Urol Nephrol."},{"issue":"25","key":"10.1016\/j.jbo.2025.100667_b0155","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","volume":"1","author":"Brown","year":"2020","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2025.100667_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2024.100611","article-title":"The impact of androgen deprivation therapy on bone microarchitecture in men with prostate cancer: a longitudinal observational study (The ANTELOPE Study)","volume":"47","author":"Handforth","year":"2024","journal-title":"J. Bone Oncol."},{"issue":"19","key":"10.1016\/j.jbo.2025.100667_b0165","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"34","key":"10.1016\/j.jbo.2025.100667_b0170","doi-asserted-by":"crossref","first-page":"S956","DOI":"10.1016\/j.annonc.2023.09.2718","article-title":"1768MO Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons","volume":"1","author":"Jones","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2025.100667_b0175","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/bonekey.2015.85","article-title":"Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review","volume":"4","author":"Bienz","year":"2015","journal-title":"Bonekey Rep."},{"issue":"14","key":"10.1016\/j.jbo.2025.100667_b0180","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1158\/1078-0432.CCR-22-3394","article-title":"Metastatic prostate cancers with BRCA2 versus ATM mutations exhibit divergent molecular features and clinical outcomes","volume":"29","author":"Hwang","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jbo.2025.100667_b0185","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2025.100667_b0190","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1464-410X.2007.06853.x","article-title":"Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid","volume":"100","author":"Ryan","year":"2007","journal-title":"BJU Int."},{"issue":"6_suppl","key":"10.1016\/j.jbo.2025.100667_b0195","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1200\/JCO.2023.41.6_suppl.46","article-title":"Whole-body diffusion-weighted magnetic resonance imaging to assess bone response in patients with hormone-sensitive metastatic prostate cancer randomly assigned to receive androgen deprivation + enzalutamide \u00b1 zoledronic acid","volume":"41","author":"Dalla Volta","year":"2023","journal-title":"JCO"},{"issue":"11","key":"10.1016\/j.jbo.2025.100667_b0200","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.jbo.2025.100667_b0205","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care Ontario guideline","volume":"38","author":"Saylor","year":"2020","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.jbo.2025.100667_b0210","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7326\/L17-0702","article-title":"Bone health and bone-targeted therapies for nonmetastatic prostate cancer","volume":"168","author":"Alibhai","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"18","key":"10.1016\/j.jbo.2025.100667_b0215","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4 Pt 1","key":"10.1016\/j.jbo.2025.100667_b0220","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-130-4-199902160-00008","article-title":"Hypocalcemia associated with alendronate","volume":"130","author":"Schussheim","year":"1999","journal-title":"Ann. Intern. Med."},{"issue":"15","key":"10.1016\/j.jbo.2025.100667_b0225","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJM200304103481521","article-title":"Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency","volume":"348","author":"Rosen","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jbo.2025.100667_b0230","first-page":"346","article-title":"Alendronate and risedronate: reports of severe bone, joint, and muscle pain","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.jbo.2025.100667_b0235","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jbo.2015.09.001","article-title":"Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: a literature review","volume":"4","author":"Kourie","year":"2015","journal-title":"J Bone Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100667_b0240","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the AMERICAN society for bone and mineral research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.jbo.2025.100667_b0245","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2025.100667_b0250","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.jbo.2025.100667_b0255","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/COC.0b013e31824be20e","article-title":"Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis","volume":"36","author":"Sun","year":"2013","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100667_b0260","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3390\/curroncol29030142","article-title":"Bone targeting agents in patients with prostate cancer: general toxicities and osteonecrosis of the jaw","volume":"29","author":"Mollica","year":"2022","journal-title":"Curr. Oncol."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137425000089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137425000089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T13:20:21Z","timestamp":1742390421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137425000089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":52,"alternative-id":["S2212137425000089"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100667","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronic acid in metastatic castrate-sensitive prostate cancer: A state-of-the-art review","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100667"}}